STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
chemistry

Apogee Therapeutics’ APG777 Demonstrates Promising Longevity in Phase 1 Study, Ahead of Key 2025 Milestones

byLuca Blaumann
October 25, 2024
in Biotechnology, Mid-Cap
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

Nine-Month Follow-Up Data Validates APG777’s Extended Half-Life and Safety, as Investors Look to Pipeline Updates and Upcoming Clinical Data

In a promising update for Apogee Therapeutics (APGE), nine-month follow-up data from the company’s Phase 1 trial of its lead therapy candidate, APG777, showed extended durability and maintained pharmacodynamic (PD) effects. This recent analysis further underscores the drug’s potential as a long-lasting treatment for inflammatory diseases, supporting prior findings on its half-life of approximately 75 days. Wedbush Securities, maintaining its Outperform rating and price target of $87 on APGE, viewed the data as a strong validation of the company’s approach and timing.

APG777 Half-Life and Pharmacodynamics Under the Microscope

The latest interim data for APG777, Apogee’s monoclonal antibody targeting specific cytokine pathways, comes from a nine-month follow-up of single ascending dose (SAD) cohorts. Previously reported results in March focused on 4-6 months of follow-up data from 18 healthy volunteers across doses ranging from 300 to 1200 mg. This new data continues to support an estimated 75-day half-life with low variability in drug exposure, indicating the possibility for quarterly (Q3M) or biannual (Q6M) dosing in future applications.

Importantly, PD markers such as STAT6 phosphorylation and TARC levels, which are indicators of immune response, remained suppressed well below baseline levels for at least nine months post-dosing. This sustained effect suggests that APG777 can effectively maintain immune modulation with extended intervals between doses, which would be an attractive feature in managing chronic inflammatory conditions like atopic dermatitis (AD) and asthma.

Favorable Safety Profile Reinforces Drug Potential

The safety profile of APG777 remains a highlight, with no severe adverse events (SAEs), treatment-emergent adverse events (TEAEs) leading to discontinuation, or Grade 3 or higher treatment-related adverse events recorded across dosing cohorts. This favorable safety data further builds confidence in APG777’s potential as it moves towards more extensive clinical trials. A reassuring aspect of the study has been the consistency of results, with the latest nine-month data aligning with PK/PD inferences made from earlier analyses at 4-6 months.

Looking Ahead: Key Milestones and New Trails

Looking forward, Wedbush anticipates several upcoming catalysts for Apogee Therapeutics, which could impact the company’s stock. Expected by the end of 2024, initial pharmacokinetic (PK) and safety data from a Phase 1 study of APG808—another promising candidate in Apogee’s portfolio—could serve as a potential positive driver. Additionally, on December 2, Apogee will host an R&D Day to outline further pipeline diversification efforts, which investors and analysts are expected to watch closely.

A major milestone for APG777 will be the 16-week efficacy data in AD, which is expected in the second half of 2025. Success in this trial could position Apogee’s therapy as a competitive treatment in the growing atopic dermatitis market. Apogee’s $87 price target from Wedbush relies on a sum-of-parts valuation that includes a projected sixfold multiple of estimated worldwide sales in AD and asthma by 2032, discounted at 25%.

A Strong Foundation with Future Potential

Overall, Apogee’s clinical data continues to reinforce confidence in its strategic focus and pipeline. With no major safety concerns and evidence of extended PD effects, APG777 shows potential for patient-friendly dosing schedules, which would provide a significant advantage in treating chronic inflammatory conditions. As Apogee moves toward its next data releases and R&D Day, investors have reason to keep a close watch on the company’s progress and upcoming clinical milestones.

This report reflects insights from Wedbush Securities.

You might like this article:L3Harris and Palantir Forge Strategic Partnership to Advance Defense Capabilities

Tags: analystGrowthMoversNewsStock Market
Previous Post

L3Harris and Palantir Forge Strategic Partnership to Advance Defense Capabilities

Next Post

Here Is What You Should Know About Joby Aviation’s Offering

Related Posts

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

byLiliana Vida
November 11, 2026
0

Quantum computing company reports $4.5 million in revenue, strong year-to-date bookings, and potential access to $100 million in federal funding....

investing

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

byLuca Blaumann
November 10, 2026
0

Quantum computing company beats earnings expectations, reports $503 million in liquidity, and advances major technology initiatives across global markets. D-Wave...

Next Post
evtol

Here Is What You Should Know About Joby Aviation's Offering

Latest News

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

Based on Your Interest

investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026
Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026

Recommended

Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Aerospace & Defense

SpaceX Secures Reported $45 Billion AI Infrastructure Deal With Anthropic

November 9, 2026
Artificial Intelligence

IonQ Revenue Surges 336% to Record $173.8 Million as Quantum Computing Demand Accelerates

November 6, 2026
Stoxpo

Follow us on social media:

Highlights

  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%
  • CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates
  • CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

November 12, 2026

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

November 11, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.